Prostate cancer: Doses and volumes of radiotherapy;Cancer de prostate : doses et volumes cibles

Cancer/Radiotherapie

Volumn 14, Issue 6-7, 2010, Pages 474-478

  Hennequin, C ^a   Rivera, S ^a   Quero, L ^a   Latorzeff, I ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b CLINIQUE PASTEUR   (France)

Author keywords

Dose effect; IMRT; Prostate cancer; Radiotherapy

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANDROGEN DEPRIVATION THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISTANT METASTASIS; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LONG TERM CARE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEMINAL VESICLE; SHORT SURVEY; TREATMENT FAILURE; ADENOCARCINOMA; ADJUVANT THERAPY; BRACHYTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; LYMPH NODE; LYMPH NODE METASTASIS; MALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; ORGAN SIZE; PATHOLOGY; PROSTATE; PROSTATE TUMOR; PROSTATECTOMY; RADIATION EXPOSURE; RADIATION INJURY; RADIATION RESPONSE; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; ORGAN SIZE; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEMINAL VESICLES;

EID: 77958175869     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2010.07.229     Document Type: Short Survey

References (53)

1. Al-Mamgani A., van Putten W.L., Heemsbergen W.D., van Leenders G.J., Slot A., Dielwart M.F., et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72:980-988.
2. Anscher M.S., Clough R., Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys 2000, 48:369-375.
3. Baccala A., Reuther A.M., Bianco F.J., Scardino P.T., Kattan M.W., Klein E.A. Complete resection of seminal vesicles at radical prostatectomy results in substantial long-term disease-free survival: multi-institutional study of 6740 patients. Urology 2007, 69:536-540.
4. Beckendorf V., Guérif S., Le Prisé é., Cosset J.M., Bougnoux A., Chauvet B., et al. 70 Gy versus 80 Gy Dose escalation GETUG 06 French trial for localized prostate cancer: mature results. Int J Radiat Oncol Biol Phys 2008, 72:S96-97.
5. Bernard J.R., Buskirk S.J., Heckman M.G., Diehl N.N., Ko S.J., Macdonald O.K., et al. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. Int J Radiat Oncol Biol Phys 2010, 76:735-740.
6. Bolla M., de Reijke T.M., Van Tienhoven G., Van den Bergh A.C., Oddens J., Poortmans P.M., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527.
7. Bolla M., van Poppel H., Collette L., van Cangh P., Vekemans K., Da Pozzo L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005, 366:572-578.
8. Cellini N., Morganti A.G., Mattiucci G.C., Valentini V., Leone M., Luzi S., et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 2002, 53:595-599.
9. Chapet O., Quero L., Azria D., Bossi A., Hennequin C., Paparel P. L'irradiation pelvienne est-elle toujours justifiée dans le traitement des cancers de la prostate par irradiation exclusive ?. Cancer Radiother 2009, 13:416-422.
10. Choo R., Morton G., Danjoux C., Hong E., Szumacher E., DeBoer G. Limited efficacy of salvage radiotherapy for biopsy confirmed or clinically palpable local recurrence of prostate carcinoma after surgery. Radiother Oncol 2005, 74:163-167.
11. Ciernik I.F., Brown D.W., Schmid D., Hany T., Egli P., Davis J.B. 3D-segmentation of the 18F-choline PET signal for target volume definition in radiation therapy of the prostate. Technol Cancer Res Treat 2007, 6:23-30.
12. Cozzarini C., Montorsi F., Fiorino C., Alongi F., Bolognesi A., Da Pozzo L.F., et al. Need for high radiation dose (≥ 70 Gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients. Int J Radiat Oncol Biol Phys 2009, 75:966-974.
13. D'Amico A., Whiington R., Malkowicz B., Schultz D., Blank K., Broderick G., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
14. D'Amico A., Whittington R., Malkowicz S., Fondurulia J., Chen M., Kaplan I., et al. Pretreatment normogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999, 17:168-172.
15. D'Amico A.V., Chen M.H., Renshaw A.A., Loffredo M., Kantoff P.W. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008, 299:289-295.
16. de Crevoisier R., Melancon A.D., Kuban D.A., Lee A.K., Cheung R.M., Tucker S.L., et al. Changes in the pelvic anatomy after an IMRT treatment fraction of prostate cancer. Int J Radiat Oncol Biol Phys 2007, 68:1529-1536.
17. Dearnaley D.P., Sydes M.R., Graham J.D., Aird E.G., Bottomley D., Cowan R.A., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487.
18. Eade T.N., Hanlon A.L., Horwitz E.M., Buyyounouski M.K., Hanks G.E., Pollack A. What dose of external-beam radiation is high enough for prostate cancer?. Int J Radiat Oncol Biol Phys 2007, 68:682-689.
19. Eggener S.E., Scardino P.T., Carroll P.R., Zelefsky M.J., Sartor O., Hricak H., et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol 2007, 178:2260-2267.
20. Engelbrecht M.R., Jager G.J., Laheij R.J., Verbeek A.L., van Lier H.J., Barentsz J.O. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 2002, 12:2294-2302.
21. Fonteyne V., Villeirs G., Speleers B., De Neve W., De Wagter C., Lumen N., et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 2008, 72:799-807.
22. Frank S.J., Dong L., Kudchadker R.J., De Crevoisier R., Lee A.K., Cheung R., et al. Quantification of prostate and seminal vesicle interfraction variation during IMRT. Int J Radiat Oncol Biol Phys 2008, 71:813-820.
23. Grills I.S., Martinez A.A., Hollander M., Huang R., Goldman K., Chen P.Y., et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004, 171:1098-1104.
24. Hanks G., Hanlon A., Epstein B., Horwitz E. Dose response in prostate cancer with 8-12 year's follow-up. Int J Radiat Oncol Biol Phys 2002, 54:427-435.
25. Hanks G., Hanlon A., Pinover Wea. Dose escalation for prostate cancer based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 2000, 46:823-832.
26. Jacob R., Hanlon A.L., Horwitz E.M., Movsas B., Uzzo R.G., Pollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 2004, 100:538-543.
27. Kestin L., Goldstein N., Vicini F., Yan D., Korman H., Martinez A. Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume?. Int J Radiat Oncol Biol Phys 2002, 54:686-697.
28. King C.R., Spiotto M.T. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 2008, 71:23-27.
29. Kuban D.A., Tucker S.L., Dong L., Starkschall G., Huang E.H., Cheung M.R., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74.
30. Kupelian P., Potters L., Khuntia D., Ciezki J., Reddy C., Reuther A., et al. Radical prostatectomy, extrenal beal radiotherapy<72 Gy, extrenal beam radiotherapy ≥ 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58:25-33.
31. Kupelian P.A., Ciezki J., Reddy C.A., Klein E.A., Mahadevan A. Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 71:16-22.
32. Lawton C.A., DeSilvio M., Roach M., Uhl V., Kirsch R., Seider M., et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007, 69:646-655.
33. Liauw S.L., Fricano J., Correa D., Weichselbaum R.R., Jani A.B. Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores. Cancer 2009, 115:1784-1790.
34. Macdonald O.K., Schild S.E., Vora S.A., Andrews P.E., Ferrigni R.G., Novicki D.E., et al. Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys 2004, 58:1530-1535.
35. Meijer G.J., de Klerk J., Bzdusek K., van den Berg H.A., Janssen R., Kaus M.R., et al. What CTV-to-PTV margins should be applied for prostate irradiation? Four-dimensional quantitative assessment using model-based deformable image registration techniques. Int J Radiat Oncol Biol Phys 2008, 72:1416-1425.
36. Pieters B.R., de Back D.Z., Koning C.C., Zwinderman A.H. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. Radiother Oncol 2009, 93:168-173.
37. Pommier P., Chabaud S., Lagrange J.L., Richaud P., Lesaunier F., Le Prisé é., et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007, 25:5366-5373.
38. Sathya J.R., Davis I.R., Julian J.A., Guo Q., Daya D., Dayes I.S., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005, 23:1192-1199.
39. Singh A.K., Guion P., Sears-Crouse N., Ullman K., Smith S., Albert P.S., et al. Simultaneous integrated boost of biopsy proven. MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Radiat Oncol 2007, 2:36.
40. Stephenson A.J., Eastham J.A. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 2005, 23:8198-8203.
41. Stephenson A.J., Shariat S.F., Zelefsky M.J., Kattan M.W., Butler E.B., Teh B.S., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004, 291:1325-1332.
42. Teh B.S., Bastasch M.D., Wheeler T.M., Mai W.Y., Frolov A., Uhl B.M., et al. IMRT for prostate cancer: defining target volume based on correlated pathologic volume of disease. Int J Radiat Oncol Biol Phys 2003, 56:184-191.
43. Thompson I.M., Tangen C.M., Paradelo J., Lucia M.S., Miller G., Troyer D., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009, 181:956-962.
44. van Lin E.N., Futterer J.J., Heijmink S.W., van der Vight L.P., Hoffmann A.L., van Kollenburg P., et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 2006, 65:291-303.
45. Viani G.A., Stefano E.J., Afonso S.L. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009, 74:1405-1418.
46. Wiegel T., Bottke D., Steiner U., Siegmann A., Golz R., Storkel S., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009, 27:2924-2930.
47. Xia P., Pickett B., Vigneault E., Verhey L.J., Roach M. Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int J Radiat Oncol Biol Phys 2001, 51:244-254.
48. Zapatero A., Valcarcel F., Calvo F., Algas R., Bejar A., Maldonado J., et al. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol 2005, 23:6561-6568.
49. Zelefsky M., Leibel S., Gaudin P., Kutcher G., Fleshner N., Venkatramen E., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998, 41:491-500.
50. Zelefsky M.J., Yamada Y., Fuks Z., Zhang Z., Hunt M., Cahlon O., et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008, 71:1028-1033.
51. Zietman A.L., Bae K., Slater J.D., Shipley W.U., Efstathiou J.A., Coen J.J., et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010, 28:1106-1111.
52. Zietman A.L., Coen J.J., Dallow K.C., Shipley W.U. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys 1995, 32:287-292.
53. Zietman A.L., DeSilvio M.L., Slater J.D., Rossi C.J., Miller D.W., Adams J.A., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294:1233-1239.